Abstract
The Cooper Companies will report quarterly results on March 5, 2026 Post Market; this preview integrates the company’s quantitative indicators and recent analyst commentary to frame expectations for revenue, margins, net income, and adjusted EPS, along with likely drivers and watch items.Market Forecast
Based on current-quarter forecast indicators, The Cooper Companies is expected to deliver revenue of 1.03 billion (up 4.96% year over year) and adjusted EPS of 1.03 (up 12.84% year over year), alongside estimated EBIT of 260.79 million (up 8.76% year over year). Forecast gross margin and net profit margin for the quarter were not disclosed; the market’s primary focus remains on revenue growth resilience and adjusted EPS expansion versus last year’s base.Within the company’s business mix, the outlook emphasizes steady contributions from contact lens-related operations and stabilization within the surgical portfolio. The business with the highest near-term growth potential remains CooperVision, supported by its scale in the last reported quarter at 709.60 million revenue; the group’s total revenue grew 4.60% year over year in that period.
Last Quarter Review
The Cooper Companies’ previous quarter delivered revenue of 1.07 billion (up 4.60% year over year), gross profit margin of 61.10%, GAAP net income attributable to shareholders of 84.60 million and a net profit margin of 7.94%, with adjusted EPS of 1.15 (up 10.58% year over year). EBIT for the quarter was 288.00 million (up 9.38% year over year), reflecting solid operating leverage on a mid-single-digit revenue increase.A key financial highlight was the company’s consistent gross margin base above 60%, providing a buffer for earnings compounding as operating expenses were well-contained relative to topline progress. Main business highlights included last quarter revenue of 709.60 million from CooperVision and 355.60 million from CooperSurgical; the overall company revenue rose 4.60% year over year in that period, demonstrating a balanced recovery trajectory across the portfolio.
Current Quarter Outlook (with major analytical insights)
Core operations: sustaining topline growth and margin discipline
The current quarter’s aggregate revenue estimate of 1.03 billion implies sustained mid-single-digit year-over-year expansion coming off a 1.07 billion base last quarter. The focus is on preserving contribution margin through targeted pricing and product mix, while maintaining operating efficiency that supports EBIT growth of 8.76% year over year against a forecast of 260.79 million. Last quarter’s 61.10% gross margin establishes an important reference level; if direct cost pressures remain contained and mix holds stable, this helps safeguard the EPS trajectory now estimated to rise 12.84% year over year to 1.03. Given the company’s last-reported net profit margin of 7.94%, even modest operating leverage can carry outsized benefit to earnings provided operating expenses scale prudently with revenue. Cost control remains a lever alongside incremental efficiency gains in manufacturing and supply. Investors will parse whether underlying margin dynamics demonstrate resilience consistent with the prior quarter’s 61.10% gross margin baseline.Growth engine: CooperVision scale and consistency
CooperVision remains the largest contributor to group sales, posting 709.60 million last quarter, or 66.62% of total revenue. Its scale underpins the current-quarter outlook, with revenue growth and margin stability collectively serving as a key foundation for EBIT and EPS beats or misses relative to estimates. Because forecast detail by segment is not disclosed, the central question is whether CooperVision’s run-rate can deliver sufficient incremental gross profit dollars to support EBIT of 260.79 million and the projected adjusted EPS of 1.03. If pricing holds and mix remains favorable, CooperVision’s breadth should enable steady conversion of revenue into operating profit even under variable cost environments. Currency will be a factor to watch in translation of non-U.S. sales, although the prior quarter’s companywide results indicate that topline and EBITDA conversion were balanced enough to lift EBIT by 9.38% year over year. The durability of these drivers is pertinent this quarter as the company seeks to maintain continuity in its revenue cadence and incremental margin flow-through.Secondary engine and watch items: CooperSurgical and product competitiveness
The second largest contributor, CooperSurgical, recorded 355.60 million last quarter, representing 33.38% of revenue. The unit’s near-term focus centers on execution and product competitiveness within its portfolio, including intrauterine devices and women’s health offerings, in a landscape where competition can affect pricing and unit trajectories. While forecast detail by segment is limited, the company’s consolidated revenue and EBIT estimates suggest that operational performance in this business is assumed to stabilize in aggregate, supporting mid-single-digit total revenue growth. Investor attention will be on whether product mix, pricing discipline, and commercial initiatives can offset competitive pressures while sustaining group-level profitability. If CooperSurgical maintains a stable contribution margin and execution timeline, it can act as a supporting pillar for EBIT and EPS expansion while CooperVision continues to anchor growth.Earnings sensitivity: revenue mix, operating leverage, and cost cadence
This quarter’s earnings path is most sensitive to the interplay between consolidated revenue growth, gross margin stability, and the scaling of operating expenses. The ability to translate an estimated 4.96% revenue increase into an 8.76% EBIT increase indicates expected operating leverage; deviations in expense timing, incentive accruals, or logistics cost can sway the degree of that leverage. On gross margin, the prior quarter’s 61.10% level provides context for what the market views as a reasonable baseline, yet the actual outcome will depend on product mix and any incremental cost of goods variability. Meanwhile, adjusted EPS, forecast to rise 12.84% year over year, reflects a combination of operational execution and potential share count and below-the-line effects; tracking EBIT-to-EPS conversion against the 260.79 million EBIT estimate will be a key analytic step for investors during the print.Cash flow and balance-sheet considerations
Although explicit cash flow guidance is not provided for the current quarter, last quarter’s profitability framework—1.07 billion revenue, 288.00 million EBIT, and 84.60 million net income—indicates a platform for healthy operating cash generation in line with earnings momentum if working capital does not materially expand. Inventory discipline and receivables collection timing could influence free cash conversion in the period, which in turn shapes flexibility for ongoing investment and return-of-capital considerations. The market will look for stable capital allocation priorities and any updated commentary on investment pacing that could affect near-term margin or cash flow cadence.Key stock-price drivers this quarter
- Revenue vs estimate and EPS quality: With revenue estimated at 1.03 billion and adjusted EPS at 1.03, the magnitude of any beat or miss—and the mix underpinning it—will likely influence share reaction. A modest revenue variance can translate into outsized EPS effects if operating leverage and below-the-line items move favorably. - Margin commentary and trajectory: Investors will scrutinize whether gross margin can remain near last quarter’s 61.10% and how operating expenses scale with revenue. Stable or improving conversion to EBIT, relative to the 260.79 million estimate, would reinforce the EPS outlook. - Segment execution: Data points on CooperVision’s underlying momentum and CooperSurgical’s competitive positioning are likely to shape expectations for the subsequent quarter. Updates on demand normalization, pricing, and product uptake can reset the market’s medium-term growth assumptions.Analyst Opinions
The majority of recent opinions since January 1, 2026 are bullish. Needham reaffirmed a positive stance on February 24, 2026, arguing that emerging competitive dynamics in intrauterine devices remain manageable and do not derail the investment case; the firm maintained a Buy view and emphasized execution within the portfolio. On February 3, 2026, Needham adjusted its price target to 99 while keeping a constructive rating, and market tracking indicated an average rating of overweight with a mean price target around 90.56. William Blair also expressed a favorable view during late January 2026, pointing to internal strategic work, governance improvements, and a product pipeline that together support the potential for earnings expansion and valuation re-rating.These perspectives align with the data path implied by this quarter’s forecasts: revenue up 4.96% year over year to 1.03 billion, EBIT up 8.76% to 260.79 million, and adjusted EPS up 12.84% to 1.03. The bullish camp emphasizes that last quarter’s reported gross margin of 61.10% provides a durable base from which modest revenue growth can translate into solid operating and earnings gains, particularly if the expense trajectory remains disciplined. They acknowledge the competitive landscape within the surgical portfolio—especially in contraceptive devices—but view current execution as calibrated to preserve group-level earnings quality. Analysts also underline the importance of CooperVision’s operational consistency and scale, which is reflected in its 709.60 million contribution last quarter and its central role in supporting EBIT conversion.
This majority view frames catalyst expectations for March 5, 2026 Post Market. A key validation point for the bullish case will be the relationship between the revenue print and EPS delivery: translating mid-single-digit revenue growth into double-digit EPS growth requires balanced gross margin performance and controlled operating expense growth. If reported EBIT approaches or modestly exceeds the 260.79 million estimate, and if adjusted EPS progresses near or above 1.03, bullish analysts are likely to view that as confirmation that the company’s execution playbook remains intact. Commentary around product mix within CooperVision and demand trends within CooperSurgical will also be influential; evidence of stable pricing and steady commercial progress would reinforce the constructive stance even if the headline revenue variance is small.
Finally, the bullish side highlights that last quarter’s year-over-year increases in revenue (4.60%), EBIT (9.38%), and adjusted EPS (10.58%) establish a pattern of improving incrementals at the group level. Replicating or modestly advancing that pattern in the current quarter would support the trajectory implied by the estimates, underpinning confidence in the sustainability of earnings growth through the next few reporting periods. Overall, the ratio of bullish to bearish opinions in the reviewed period is decisively in favor of the bullish camp, and the arguments presented by Needham and William Blair revolve around operational execution, balanced margins, and a revenue mix capable of driving ongoing EBIT and EPS improvements.
Comments